Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases.
Fabian SpethJohannes-Peter HaasClaas H HinzePublished in: Pediatric rheumatology online journal (2016)
This is a case series and data were retrospectively registered.